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Abstract Insulin-like growth factor (IGF) I does not quantita-
tively form its three native disulfide bonds in the presence of 10
mM reduced and 1 mM oxidized glutathione in vitro [Hober, S.
et al. (1992) Biochemistry 31, 1749^1756]. In this paper, we show
(i) that both IGF-I and IGF-II are unable to form and maintain
their native disulfide bonds at redox conditions that are similar to
the situation in the secretory vesicles in vivo and (ii) that the
presence of protein disulfide isomerase does not overcome this
problem. The results indicate that the previously described
thermodynamic disulfide exchange folding problem of IGF-I in
vitro is also present in vivo. Speculatively, we suggest that the
thermodynamic disulfide exchange properties of IGF-I and II are
biologically significant for inactivation of the unbound growth
factors by disulfide exchange reactions to generate variants
destined for rapid clearance.
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1. Introduction
Human insulin-like growth factor I (IGF-I) is a single-chain
peptide hormone of 70 amino acids which is homologous to
proinsulin [1,2]. The single-chain polypeptide growth factor
has six cysteine residues forming three disul¢de bonds (Fig.
1). A three-dimensional model of IGF-I, based on the crystal
structure of insulin, has been proposed by Blundell et al. [3]
and the model has been corroborated by NMR spectroscopy
[4,5].
IGF-I was originally isolated from serum [2]. The growth
factor is synthesized by many di¡erent cell types and tissues,
and it is thought to mediate most of the mitogenic and meta-
bolic in vivo e¡ects of growth hormone [6]. In serum and
other extracellular £uids, most of the IGF-I is carried by at
least seven di¡erent, but homologous, carrier proteins, desig-
nated IGFBP-1 to IGFBP-7 [7^9]. A number of papers report
the di¡erent activities of these seven binding proteins includ-
ing regulating half-life in circulation, transporting IGF-I to
speci¢c tissues, preventing hypoglycemia by inhibiting the
binding of IGF-I to the insulin receptor [10,11] and mediating
p53-induced cell cycle arrest [12,13].
We [14] and others [15] have previously reported a thermo-
dynamic folding problem of IGF-I in vitro to form its native
disul¢de bonds. During refolding under redox conditions that
normally favor the formation of protein disul¢des (10 mM
reduced glutathione (GSH) and 1 mM oxidized glutathione
(GSSG), respectively) [16] several di¡erent forms of IGF-I are
found, including two distinct three-disul¢de species, di¡ering
only in their disul¢de bond arrangements [14]. One of these
forms of IGF-I has the native disul¢de bonds expected from
comparison with insulin and this molecular species stimulates
proliferation through the IGF-I receptor (Fig. 1) [17,18]. The
other form, designated ‘mismatch’, has two non-native disul-
¢de bridges (6^47 and 48^52 instead of the native, 6^48 and
47^52) and lacks a⁄nity for the IGF-I receptor [17,19]. This
unusual folding behavior has been further con¢rmed by fold-
ing analysis of disul¢de mutants of IGF-I [20]. We have also
demonstrated that the presence of equimolar amounts of
IGFBP-1 will e⁄ciently overcome the folding problem of
IGF-I in vitro, suggesting that IGFBPs may function to
form and maintain correct disul¢des of IGF-I in vivo [21].
The redox state of the secretory pathway has been described
to be more oxidative than our previous in vitro experiments
[14,21] with a ratio of reduced to oxidized glutathione within
the secretory pathway from 1/1 to 3/1 [22]. In addition, the
redox potential in serum, though variable, is normally even
more oxidizing [23]. Since there are several di¡erent equili-
brium constants to consider, one for each disul¢de in a dis-
tinct conformation, and only some of these are known [14],
the ¢nal in vivo distribution of IGF-I variants cannot be
predicted. The knowledge of individual equilibrium and rate
constants is not enough to interpret the global folding behav-
ior of the intact molecule. Also, this has led to disputes in the
literature [24,25]. Therefore we have extended our analysis to
redox conditions similar to the situation in the endoplasmic
reticulum (ER). Furthermore, the disul¢de exchange folding
properties of IGF-I have been analyzed in the presence of
bovine protein disul¢de isomerase (PDI). PDI is abundant
in the secretory vesicles [26] and has been demonstrated to
act as a true catalyst of disul¢de bond formation and isomer-
ization in vitro to form native protein disul¢des in many dif-
ferent proteins, for example insulin [27]. If PDI possessed
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di¡erent accessibility to the various disul¢de bonds of IGF-I
as previously proposed [28], the distribution of di¡erent IGF-I
variants could be a¡ected in high (mM levels) PDI concen-
trations in the ER. The disul¢de exchange folding properties
of IGF-II have also been analyzed. This growth factor shows
di¡erent molecular endocrinological properties from IGF-I,
including a separate receptor [2]. However, IGF-II is carried
by the same set of IGFBPs as IGF-I. Therefore, this growth
factor is also a candidate for dependence on IGFBP to form
and maintain correct disul¢des.
The results presented in this paper suggest that IGF-I pos-
sesses a thermodynamic folding problem in vivo and is de-
pendent on IGFBP for correct folding. Interestingly, IGF-II
shares these unusual folding properties. These results are uti-
lized to propose a mechanism of inactivation of IGF-I and
IGF-II involving disul¢de exchange reshu¥ing of the native
disul¢des.
2. Materials and methods
2.1. Materials
Native and mismatch forms of IGF-I were produced and puri¢ed as
fusion proteins in Escherichia coli and the di¡erent IGF-I forms were
separated on reverse-phase HPLC [19,29,30]. Recombinant IGF-II
was produced in E. coli as described previously [31]. BPTI was kindly
provided by Bayer AG, Germany. Bovine PDI was puri¢ed as de-
scribed by Lundstroºm et al. [32].
Reduced protein (IGF-I, IGF-II or BPTI) was prepared according
to Hober et al. [14].
2.2. Protein analysis
Protein concentrations for native and mismatch IGF-I were calcu-
lated from quantitative amino acid analysis as described by Hober et
al. [14].
The concentration of reduced IGF-I and PDI was determined by
measuring the absorbance at 280 nm using a spectrophotometer
(Kontron, Switzerland) and calculating the protein content by using
the speci¢c absorption constant A280 (1 cm, 1 mg/ml) = 2.1 for IGF-I
[14] and 0.8 for PDI [32].
Molecular masses were determined using a 252Cf plasma desorption
mass spectrometer, Bio-Ion 20 (Applied Biosystems, USA) [14], or a
Jeol SX102 mass spectrometer equipped with an electrospray unit
(Jeol, Japan).
2.3. Disul¢de exchange reactions
Disul¢de exchange reactions were performed at 37‡C for 1 h, at a
protein concentration of 30 WM. The bu¡er used contained 0.1 M
Tris, pH 8.7, 0.2 M KCl, 1 mM EDTA, and di¡erent concentrations
of GSSG (1, 2, 5, 10, or 10 mM) and GSH (10, 10, 5, 2, or 1 mM),
respectively. Where applicable, bovine PDI was added to the reaction
mixture to a ¢nal concentration of 1, 10, or 30 WM. Disul¢de ex-
change reactions were quenched by pyridylethylation of free thiols
with 160 mM vinyl pyridine (VP) [33]. The alkylation reaction was
allowed to proceed for 15 min in the dark [14]. Thereafter, the bu¡er
was immediately exchanged to 10 mM HCl by ultra¢ltration (Centri-
con 3, microconcentrator, Amicon) or by gel ¢ltration using Sephadex
G-25 (Pharmacia, Sweden).
Di¡erent IGF-I variants were separated by reverse-phase HPLC
according to Hober et al. [14]. Molecular masses of material isolated
from each peak revealed possible numbers of covalently bound pyr-
idylethyl or glutathione groups. The presence of pyridylethyl groups
was also detected by its chromophore, showing a strong absorbance at
254 nm [14] (data not shown). The relative quantities of IGF-I in the
di¡erent peaks were determined by integrating their £uorescence spec-
tra (excitation at 280 nm and emission at 305 nm) (Fig. 3), which has
been demonstrated to be similar for the di¡erent forms of IGF-I [14].
Pyridylethyl groups do not add to the £uorescence of IGF-I and the
relative numbers of pyridylethyl groups could be determined by divid-
ing the integrated absorbance at 254 nm and the integrated £uores-
cence [14].
Separation of di¡erent IGF-II variants were performed as described
for IGF-I but with a gradient of 33^48% in 50 min. Similarly, for the
separation of BPTI variants, the gradient used was 25^40% in 30 min.
2.4. Calculations
Relative free energies in the presence of reduced and oxidized glu-
tathione were calculated relative to native IGF-I from determined
equilibrium constants (K) using the equation vG =3RT ln (K).
3. Results
3.1. Refolding of IGF-I under di¡erent redox conditions
Native, mismatch and reduced IGF-I were equilibrated in
glutathione redox bu¡ers di¡ering in their respective concen-
trations of GSSG and GSH. Ratios of GSH/GSSG [mM/mM]
used were 10/1, 10/2, 5/5, 2/10, or 1/10, respectively (Table 1).
As a control, reduced IGF-I was incubated for 1 h in the
absence of glutathione, resulting in only minor oxidation of
IGF-I. Thus, we conclude that the reduced and oxidized glu-
tathione is responsible for essentially all of the observed di-
sul¢de exchange reactions under the conditions used. Since
the results using di¡erent starting materials (reduced, mis-
match and native, respectively) were indistinguishable, it
could be concluded that equilibrium had been established
for all conditions used (data not shown). In fact, the disul¢de
exchange equilibrium of IGF-I under these conditions is
formed within 5^10 min (data not shown). In Fig. 2, results
from an experiment starting from reduced IGF-I are shown.
The di¡erent forms of IGF-I isolated from the equilibrium
mixtures were analyzed. The number of pyridylethylated thi-
ols of each IGF-I form was determined by dividing the inte-
grated absorbance at 254 nm and the integrated £uorescence
[14] (Table 2). The identities of the di¡erent isolated major
IGF-I components in the equilibrium mixtures were further
analyzed by peptide mapping techniques and by retention
time comparison in RP-HPLC [14] (Table 2). Relative
amounts of IGF-I were determined by the integrated £uores-
cence (Table 1, Fig. 3). This is a previously validated method
for quantitative analyses of relative amounts of IGF-I [14].
A separate experiment was performed as a control for pos-
sible artifacts due to the alkylation reaction. The disul¢de
exchange folding reactions in the 10 mM GSH/1 mM GSSG
equilibrium mixture were slowed down by lowering the pH to
2 with HCl. The di¡erent folding variants were without delay
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Fig. 1. A two-dimensional representation of IGF-I. The amino acids
are shown as circles and written in one-letter code. The disul¢des
are connected as in the native structure of IGF-I. Helices are indi-
cated by boxes. The fragments A, B, C, D and E are named accord-
ing to the nomenclature of insulin.
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separated by RP-HPLC and collected. All isolated IGF-I spe-
cies were alkylated with VP at alkaline pH and reanalyzed by
RP-HPLC. Each isolated molecular species was maintained as
a single peak after alkylation demonstrating that no detect-
able disul¢de rearrangement occurred during alkylation. In
addition, retention times and absorbance at 254 nm revealed
that the distribution of intermediates was indistinguishable
from the original VP-trapping experiment [14]. These results
suggest that the IGF-I equilibrium is unaltered during the
pyridyl ethylation under the conditions used.
3.2. Analysis of the di¡erent equilibrium mixtures
3.2.1. 10 mM GSH/1 mM GSSG. The 1/10 redox condi-
tions are identical to what has been utilized previously to
de¢ne the thermodynamic folding problem of IGF-I [14,21].
It is also identical to what is commonly used to study disul¢de
exchange folding of proteins [16,34,35]. Five di¡erent forms of
IGF-I, isolated from the equilibrium mixture (2A^7A), were
analyzed. The obtained results are similar to what has been
described by us earlier [14] (Tables 1 and 2, Figs. 2 and 3).
3.2.2. 10 mM GSH/2 mM GSSG. Materials from ¢ve dif-
ferent peaks (data not shown) were isolated and analyzed
(Table 1, Fig. 3).
3.2.3. 5 mM GSH/5 mM GSSG. Material from six sepa-
rate peaks (1B^8B) was isolated and further analyzed (Tables 1
and 2, Figs. 2 and 3).
3.2.4. 2 mM GSH/10 mM GSSG. Three di¡erent peaks
(data not shown) were isolated and analyzed (Table 1, Fig. 3).
3.2.5. 1 mM GSH/10 mM GSSG. Materials from four dif-
ferent peaks (1C^8C) were isolated and analyzed. The mass,
the absorbance at 254 nm, comparison of retention times in
the HPLC system and peptide mapping gave the identity of
the peaks (Tables 1 and 2, Figs. 2 and 3).
Relative amounts of native and mismatch IGF-I in the
di¡erent redox bu¡ers were used to calculate free energies
relative to native IGF-I from equilibrium constants (Table 1).
Under all redox conditions tried we found at least four
di¡erent IGF-I variants (Fig. 2). Their relative amounts var-
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Table 2
PDMS analysis of material in the peaks from RP-HPLC (Fig. 2)
Peak Designation Number of VP Number of GS Calculated mass Measured mass
1Ba,1Cb;c mixed 0 2 8262.2 8261.8
2Ab,2Bb,2Cb IIIP 0 0 7649.6 7649.3
3Aa,3Bb II 2 0 7859.9 7860.9
4B II-mix 1 1 8061.0 8061.0
5Ab,5Bb,5Cb III 0 0 7649.6 7648.8
6Aa IIQ 2 0 7859.9 7861.0
7Aa I 4 0 8070.2 8069.5
8Bb,8Cb III? 0 0 7649.6 7648.9
The numbers of disul¢de bonds in the intermediates are indicated in Roman numerals. A prime after the Roman numeral indicates a molecule
where all formed disul¢des are as in the mismatch form of IGF-I. Two primes after the Roman numeral indicates at least one disul¢de bridge which
is found neither in the native nor in the mismatch form of IGF-I.
aIdentity determined by peptide mapping techniques.
bIdentity determined by retention time comparision in RP-HPLC.
cPeptide mapping of the material in this peak revealed that the 18^61 disul¢de was formed.
Table 1
Amounts and relative free energies of native (III) and mismatch
(IIIP) IGF-I in di¡erent redox potentials
GSSG/GSH III
(%)
IIIP
(%)
Ratio III/IIIP vvG
(kcal/mol)
1/10 22 7 3.1 0.7
1/5 29 13 2.2 0.5
1/1 42 23 1.8 0.4
5/1 51 27 1.9 0.4
10/1 51 27 1.9 0.4
The di¡erences in relative energy were calculated relative to native
IGF-I.
Fig. 2. RP-HPLC separation of di¡erent IGF-I variants from VP-
trapped folding mixtures. The gradient was linear, 30^45% acetoni-
trile in 0.25% PFPA, over 30 min. The £uorescence (excitation at
280 nm and emission at 305 nm) of the di¡erent peaks was moni-
tored. The chromatograms show the analyses of IGF-I samples after
incubation in di¡erent redox bu¡ers. The major peaks are numbered
according to the order of migration and are further described in the
text. Ratios (1/10, 5/5, 10/1) denote the GSH/GSSG concentrations
in mM/mM.
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ied with the redox conditions (Fig. 3). Even in the most ox-
idative environment tested, more oxidative than what has
been proposed to exist in the secretory pathway [22], we found
only about 65% of IGF-I as three disul¢de species. The ratio
between native and mismatch IGF-I is about the same in the
di¡erent glutathione concentrations tried. As expected, the
relative amount of three disul¢de-bonded species of IGF-I
increases with increasing redox potential.
3.3. Disul¢de exchange equilibrium of IGF-I in a glutathione
bu¡er in the presence of PDI
The disul¢de exchange equilibrium folding properties of
IGF-I were analyzed in a bu¡er containing 10 mM GSH,
1 mM GSSG and 1, 10, or 30 WM of PDI. The disul¢de
exchange reaction was trapped using VP and di¡erent species
were analyzed using RP-HPLC. PDI elutes later in the chro-
matogram than all previously analyzed IGF-I equilibrium var-
iants (data not shown). Fig. 4 shows a chromatogram from a
refolding reaction which started from reduced IGF-I in the
presence of 10 WM PDI. The results appear indistinguishable
from refolding reactions starting from native hormone and/or
with other concentrations of PDI. The results demonstrate
that catalytic or equimolar amounts of PDI per se do not
overcome the thermodynamic folding problem of IGF-I.
3.4. Disul¢de exchange folding of IGF-II
Oxidized IGF-II was incubated for 1 h in glutathione buf-
fers at two di¡erent redox conditions, 10 mM or 1 mM GSH
and 1 mM or 10 mM GSSG, respectively. Thus, this redox
range will span what was used for IGF-I, but with only two
di¡erent conditions (GSH/GSSG 10/1 and 1/10, respectively).
The disul¢de exchange reactions were trapped with VP similar
to the conditions used for IGF-I [14]. The di¡erent disul¢de
species were separated by RP-HPLC (Fig. 5). The materials in
di¡erent peaks were collected and analyzed with mass spec-
trometry, UV absorbance spectroscopy and £uorescence (ex-
citation at 280 nm and emission at 305 nm). The masses and
the ratio of the integrated absorbance at 254 nm and the
integrated £uorescence revealed the possible number of cova-
lently bound pyridylethyl groups. Based on these two results,
the two predominant peaks in 10 mM GSH and 1 mM GSSG
are a three-disul¢de species (A1) and a one-disul¢de species
(A2). When refolded at 1 mM GSH and 10 mM GSSG, we
found one IGF-II variant with two disul¢des and two cys-
teines with glutathione covalently bound (B1), and two
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Fig. 5. A: RP-HPLC separation of di¡erent IGF-II variants from
VP-trapped equilibrium mixtures. The gradient was linear, 33^48%
acetonitrile in 0.25% PFPA, over 50 min. The £uorescence (excita-
tion at 280 nm and emission at 305 nm) of the di¡erent peaks was
measured. The chromatograms show samples from incubations in
bu¡ers at di¡erent redox conditions. The major peaks are numbered
according to the order of migration. B: BPTI variants from VP-
trapped equilibrium folding mixtures. The folding bu¡er has a con-
centration of 10 mM GSH and 1 mM GSSG. The upper chromato-
gram shows a reference with oxidized BPTI. The gradient was line-
ar, 30^50% acetonitrile in 0.25% PFPA, over 30 min. The
£uorescence (excitation at 280 nm and emission at 305 nm) of the
di¡erent peaks was measured. Ratios (1/10, 10/1) denote the GSH/
GSSG concentrations in mM/mM.
Fig. 4. RP-HPLC separation of di¡erent IGF-I variants from VP-
trapped folding mixtures. The lower chromatogram (a) shows a
sample from incubation in a bu¡er with PDI. The upper chromato-
gram (b) shows a sample from an identical redox bu¡er but without
PDI. The concentration of glutathione in the bu¡er was 10 mM
GSH and 1 mM GSSG. The gradient was linear, 30^45% acetoni-
trile in 0.25% PFPA, over 30 min. The £uorescence (excitation at
280 nm and emission at 305 nm) of the di¡erent peaks was meas-
ured.
Fig. 3. Relative amounts of di¡erent IGF-I species vary with the re-
dox potential. The percentages are calculated according to the total
peak area from the RP-HPLC chromatograms (Fig. 2). Di¡erent
molecular species are marked as the designation in Table 2. Ratios
(1/10, 2/10, 5/5, 10/2, 10/1) denote the GSH/GSSG concentrations in
mM/mM.
S. Hober et al./FEBS Letters 443 (1999) 271^276274
three-disul¢de species (B2 and B3). Even though detailed anal-
ysis of the di¡erent IGF-II forms in the mixtures should be
corroborated with detailed disul¢de mapping, these result im-
plies that IGF-II possesses a similar thermodynamic folding
problem as was previously reported for IGF-I [14].
3.5. Disul¢de exchange of BPTI
Native and reduced BPTI were incubated in GSH/GSSG
redox bu¡ers and subsequently alkylated with VP. In both
redox conditions studied (10 mM or 1 mM GSH and 1 mM
or 10 mM GSSG, respectively) starting from either oxidized
or reduced BPTI, after pyridylethylation using VP, we found
only one major peak in the HPLC analysis (Fig. 5). The
retention time, mass and the absorbance at 254 nm were iden-
tical to what was found for the native three-disul¢de form of
BPTI. Thus, as predicted from other reports [36], BPTI is able
to refold and maintain its native disul¢de bonds in the redox
range tested and under the conditions used.
4. Discussion
In this paper we have analyzed disul¢de formation of IGF-I
in di¡erent glutathione redox conditions (Table 1). A broad
range of di¡erent glutathione redox conditions has been tried,
including conditions similar to those reported for the secre-
tory pathway of eukaryotic cells [22]. Since IGF-I theoreti-
cally has 75 possible disul¢de conformations, there are several
unknown equilibrium constants to consider. Therefore it is
hard to predict the ¢nal distribution of di¡erent IGF-I var-
iants, based on the limited number of previously identi¢ed
equilibrium constants for the formation of individual disul-
¢des. Similar components and amounts were found at equili-
brium under each redox condition starting from either re-
duced, mismatch or native IGF-I demonstrating that an
equilibrium had been established. From the experiments we
conclude that IGF-I is unable to quantitatively maintain its
native three-disul¢de conformation under all conditions tried.
The predominant variants of IGF-I under the conditions
tested were isolated and most of these were identi¢ed (Table
2). In the redox range tested, native IGF-I increased from
22% to 51% and mismatch from 7% to 27% (Table 1), going
to more oxidizing conditions. Interestingly, the relative pro-
portions of native to mismatch IGF-I are essentially constant
through the redox range; the relative free energies between
these two forms are kept in a rather narrow range (0.4^0.7
kcal/mol) (Table 1). Comparison of the amounts of di¡erent
disul¢de variants of IGF-I shows that the similar thermody-
namic folding energies probably are due to a similar structural
folding core. IGF-I is a rather £exible molecule and the hy-
drophobic core that stabilizes the three-dimensional structure
is small [4,37]. By making disul¢de mutant proteins and study-
ing their structure it has been possible to conclude that IGF-I
is dependent on, at least, the 6^48 and 47^52 disul¢de bonds
to keep the structure of the native molecule [20,37,38]. The
structural content of the di¡erent disul¢de mutants and those
lacking disul¢des has been compared by circular dichroism.
From these studies one can conclude that all disul¢de variants
have at least partly ordered structure [14,20,37,38]. Also, anal-
yses of the a⁄nity constants of the mutated molecules to-
wards the IGF-I receptor and the IGF-BP-1 suggest partly
native-like structures [20,38]. Through NMR studies on an
alanine model of IGF-I lacking the 47^52 disul¢de, Hua et
al. [37] have demonstrated that the removal of one disul¢de is
associated with a local unfolding of the second K-helix. In the
native structure this helix is connected to the hydrophobic
core by the 47^52 disul¢de. These results indicate that the
small folding core, similar for the di¡erent folding species, is
located around the 18^61 disul¢de.
Redox equilibria were established for IGF-II in two di¡er-
ent redox conditions (Fig. 5). The results demonstrate that the
three native disul¢de bonds are not quantitatively formed in
IGF-II under the conditions used, suggesting that also IGF-II
is unable to quantitatively form and maintain its native disul-
¢des. This result suggests that IGF-II may utilize IGFBP to
form its native disul¢des in vivo, as has been demonstrated for
IGF-I in vitro [21]. In contrast, as expected from the known
equilibrium constants of the individual disul¢des of BPTI [36],
the BPTI molecule maintains its native disul¢des in both
tested redox potentials (Fig. 5).
Thus, the disul¢de equilibrium studies under the di¡erent
redox conditions utilized in this paper suggest that IGF-I and
IGF-II cannot by themselves form or maintain their disul¢des
in vivo. The obvious question is how IGF-I and IGF-II over-
come this problem. We have previously shown that the IGF-I
precursor, IGF-I-Ea, has similar disul¢de exchange folding
properties as mature IGF-I and is therefore unlikely to play
any role in shifting the disul¢de exchange equilibrium proper-
ties of the growth factor during folding [21]. As demonstrated
in this paper, the protein PDI, which is responsible for the
disul¢de bond formation in the lumen of the ER in eukaryotic
cells, seems to act as a true catalyst with very little e¡ect on
the disul¢de exchange equilibrium of IGF-I under the condi-
tions used (Fig. 4). Also when equimolar amounts of the
disul¢de isomerase are used the distribution of di¡erent
IGF-I variants is rather unchanged. Accordingly, Joly and
Swartz showed [39] that DsbA, a disul¢de isomerase from
E. coli, is able to catalyze disul¢de shu¥ing of IGF-I, but
the ratio of native to mismatch seemed to be una¡ected. It
has previously been shown in vitro that IGFBP could aid in
the formation of native disul¢des of IGF-I through binding
only the native IGF-I molecule [21]. Thus, the previously pre-
sented IGFBP model for how native disul¢des might be
formed and maintained in vivo is consistent with data pre-
sented in this paper. In this mechanism, IGF-I folds into a
native state assisted by binding to the IGFBP, at the precur-
sor level (IGF-I-E) or in the form of the mature IGF-I poly-
peptide. In fact, IGFBP has been demonstrated to assist in the
folding of both IGF-I and IGF-I-E in vitro [21].
Our model for a folding switch for inactivation of IGF-I/
IGF-II has not been demonstrated in vivo. While the redox
conditions used are similar to the in vivo situation, one might
suspect that the alkaline pH (8.7) could create in vitro arti-
facts. We have repeated the equilibrium disul¢de exchange
reactions at neutral pH in the presence and absence of PDI.
The only di¡erence is the rate at which equilibrium is reached,
up to 24 h. Using such long incubations would require strict
anaerobic conditions, in practice impossible to obtain. We
chose to continue the experiments at pH 8.7 and conclude
that the properties now established for IGF-I most likely
are signi¢cant for its folding in vivo.
The similar three-dimensional structure of insulin and the
insulin-like molecules (IGF-I and IGF-II) raises the question
why the folding information is speci¢ed in the insulin case but
not in the cases of IGF-I and IGF-II. Even though the native
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fold for insulin and the insulin-like molecules is very similar
and also the amino acid sequence, there are signi¢cant di¡er-
ences in their disul¢de exchange folding behavior. This is,
however, not very surprising because small changes in primary
structure might cause large changes in the overall fold, since
the relative importance of di¡erent amino acids varies. Hua et
al. claim that the molecules’ relative stabilities are due to
variabilities in the side chains of the A and B domains of
the molecules [40]. Also, Dalal et al. have shown that chang-
ing less than 50% of the sequence identity of a former L-sheet
protein gives a four-helix bundle conformation [41]. We pro-
pose that the di¡erence in these molecule foldabilities are of
crucial evolutionary importance. Hence, the rationale behind
this IGFBP folding mechanism is probably to construct a very
reliable switch so that IGF-I and -II lose their three-dimen-
sional structures as well as biological activities in the absence
of IGFBP and thereafter are rapidly cleared. This hypothesis
is corroborated by the demonstrated inability of IGF-I and
IGF-II to maintain their native three-disul¢de conformation
in the broad redox range analyzed in this report, covering
redox ranges found both in the secretory machinery [22] and
in the circulation [23]. Why would IGF-I and IGF-II evolve
such molecular switches? IGF-I and IGF-II bind two orders
of magnitudes more weakly than insulin to the insulin recep-
tor, but the concentrations of IGF-I and IGF-II are rather
high in serum. In adult man, normal concentrations of IGF-I
are about 200 ng/ml and of IGF-II 700 ng/ml, about 1000
times that of insulin [2]. In the absence of IGFBP, IGF-I
and IGF-II would cause a hypoglycemic response [8,10].
Therefore, a dependence on IGFBP to form and maintain
the disul¢des of IGF-I and IGF-II could guarantee a rapid
clearance in the absence of IGFBP. Thus, a hypoglycemic
reaction would be minimized if the normally tightly regulated
IGFBP levels in circulation or locally would decrease under
the IGF levels. The disul¢de exchange folding switch pro-
posed in this paper could be general, and could be found
also in other molecular systems. Carrier proteins are found
for many growth factors, including growth hormone and epi-
dermal growth factor [42]. It is possible that a folding depend-
ence on the carrier protein is relevant also for some of these
other growth factors in addition to the IGF-I/IGF-II system.
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